| Name | Title | Contact Details |
|---|
We are fundamentally dedicated to biopharmaceutical innovators Building a company with this unique mission requires a different philosophy. Which is why Atlantic Research Group's founders built the company on responsive and flexible points of view.
The DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to 9.5 million Military Health System beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS. The DHA oversees the delivery of health care services like the TRICARE Health Plan, pharmacy, public health, and health information technology. DHA carries out these operations using a global health care network of military and civilian medical professionals and more than 400 military hospitals and clinics. This network strengthens the delivery of health care to MHS beneficiaries by merging proven clinical and business practices and emphasizing the experience of the patient. Exciting changes are taking place as we are in the process of reorganizing how we manage the military`s medical centers, hospitals and clinics around the world, shifting administration and management responsibility for these facilities from the Army, Navy and Air Force to the Defense Health Agency. A single integrated system will support improvements to the readiness of our operational and medical forces to meet our missions around the world, while providing outstanding care to all of those who depend on us, on the battlefield and at home.
Ashley Glen Assisted Living is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CBR International Corp is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.